Desert Metals Ltd (DM1)

Overview

Island Pharmaceuticals Limited is a pioneering drug research and repurposing company with a focused dedication to the development of innovative preventative or therapeutic drugs aimed at viral infections. Established in 2017 and headquartered in Camberwell, Australia, the company operates with a global perspective, targeting markets in both Australia and the United States of America. Island Pharmaceuticals stands out for its strategic collaborations with prestigious institutions such as Monash University, the National Cancer Institute IND, and the U.S. Army. These partnerships underline the company's commitment to advancing its research and clinical studies, particularly as it moves towards the Phase 2a/b clinical trial for its flagship product, ISLA-101.

Products and Services

• ISLA-101 - the lead product candidate developed by Island Pharmaceuticals, is a groundbreaking drug designed for the prevention and treatment of dengue fever as well as other mosquito-borne diseases. This innovative therapeutic solution highlights the company's focus on addressing some of the world's most pressing health concerns through advanced scientific research and development. The imminent progression into Phase 2a/b clinical studies signifies a significant step forward in the fight against these pervasive illnesses.
• Collaboration Agreements - Island Pharmaceuticals is engaged in notable collaboration agreements with Monash University and the National Cancer Institute IND. These collaborations reflect the company's strategy to leverage external expertise and resources to enhance its research capabilities and expedite the development of its product pipeline. Additionally, the cooperative research and development agreement with the U.S. Army emphasizes the strategic importance of ISLA-101 within the context of global health security and the military's interest in effective preventive measures against mosquito-borne diseases.